by Organ transplant immunosuppressant drugs are used to prevent organ rejection after liver, kidney or other organ transplant surgeries. They help suppress the immune system’s response to a transplanted organ, allowing the organ to function in the body without being rejected.
The global Organ Transplant Immunosuppressant Drugs Market is estimated to be valued at US$ 5.17 Bn or Mn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the organ transplant immunosuppressant drugs market is the rise in the number of organ transplant procedures across the world. According to the Global Observatory on Donation and Transplantation, over 150,000 solid organ transplant procedures are performed annually worldwide. Growing organ failure cases due to chronic diseases such as diabetes, cardiovascular diseases and cancer is a major factor driving the need for organ transplants. According to the American Transplant Foundation, every 10 minutes, someone is added to the national organ transplant waiting list. However, only about half of those in need actually receive a transplant due to shortage of organs. This has created significant growth opportunities for immunosuppressant drug manufacturers. Another important trend is the development of novel drugs with fewer side effects to replace older transplant drugs with high toxicity levels. This, along with other advancements in transplantation science, is expected to boost market growth over the forecast period.
SWOT Analysis
Strength: Organ transplant immunsuppressant drugs have well established formulations and protocols for their use. They help suppress the immune system and prevent organ rejection.
Weakness: Long term use of immunosuppressant drugs can increase risk of infections and cancer. They also have several side effects like nausea, vomiting, loss of appetite etc.
Opportunity: Growing number of organ transplant procedures worldwide is driving the demand for effective immunosuppressant drugs. Development of novel therapies with improved efficacy and safety profiles can capture more market share.
Threats: Stringent regulations for approval of transplant drugs. Patent expiry of blockbuster drugs resulting in cheaper generic competition.
Key Takeaways
The Global Organ Transplant Immunosuppressant Drugs Market Growth is expected to witness high, exhibiting CAGR of 3.1% over the forecast period, due to increasing number of organ transplant procedures worldwide.
Regional analysis
North America is expected to dominate the organ transplant immunosuppressant drugs market owing to large patient pool, rising healthcare expenditure, and presence of leading market players. Asia Pacific region is anticipated to exhibit fastest growth due to growing medical tourism industry and increasing healthcare awareness.
Key players
Key players operating in the Organ Transplant Immunosuppressant Drugs market are Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., TFF Pharmaceuticals, Inc., TolerogenixX GmbH, Veloxis Pharmaceuticals Inc., Dr. Reddys Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and Hoffman La Roche.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
